Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis

Company Overview

Oric Pharmaceuticals is a clinical-stage biotechnology company focused on developing precision medicines for patients with solid tumors that have developed resistance to current therapies. The company’s research efforts center on small molecule agents designed to overcome mechanisms of treatment escape and enhance the durability of existing anticancer regimens.

The company’s lead product candidates include ORIC-101, a selective glucocorticoid receptor antagonist being evaluated for patients whose tumors exhibit therapy-induced resistance, and ORIC-533, a potent inhibitor of the ATR kinase that is designed to exploit defects in the DNA damage response pathway. Both programs are advancing through early-stage clinical trials, with Oric providing biomarker-directed patient selection and combination strategies to maximize therapeutic benefit.

Founded in 2019 and headquartered in Redwood City, California, Oric Pharmaceuticals has built a streamlined infrastructure to support its clinical development activities across North America and Europe. The company leverages strategic partnerships and external collaborations to accelerate its pipeline, secure trial sites and integrate translational research insights into trial design.

Through an experienced leadership team with deep expertise in oncology drug development, Oric aims to deliver innovative treatments to address significant unmet medical needs. By combining targeted mechanisms of action with precision patient selection, the company seeks to improve outcomes for cancer patients who have exhausted standard treatment options.

Key Stats

• Today's Range: $10.88 to $11.41
• 50-Day Range: $4.73 to $11.45
• 52-Week Range: $3.90 to $14.67
• Volume: 480,474 shs
• Average Volume: 784,173 shs
• Market Capitalization: $938.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.57
• Consensus Rating: Buy

Oric Pharmaceuticals Stock Analysis - MarketRank™

Oric Pharmaceuticals scored higher than 91% of companies evaluated by MarketBeat, and ranked 92nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Oric Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oric Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oric Pharmaceuticals are expected to grow in the coming year, from ($2.17) to ($1.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oric Pharmaceuticals is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oric Pharmaceuticals is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oric Pharmaceuticals has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.84% of the float of Oric Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oric Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Oric Pharmaceuticals has recently decreased by 1.02%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oric Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Oric Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.16

Percentage of Shares Shorted

15.84% of the float of Oric Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oric Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Oric Pharmaceuticals has recently decreased by 1.02%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.75

News Sentiment

Oric Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Oric Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oric Pharmaceuticals insiders have sold 58.30% more of their company's stock than they have bought. Specifically, they have bought $262,976.00 in company stock and sold $416,289.00 in company stock.

Percentage Held by Insiders

Only 6.82% of the stock of Oric Pharmaceuticals is held by insiders.

Percentage Held by Institutions

95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ORIC Stock Analysis - Frequently Asked Questions

How have ORIC shares performed this year?

Oric Pharmaceuticals' stock was trading at $8.07 at the start of the year. Since then, ORIC shares have increased by 36.4% and is now trading at $11.01.

How were Oric Pharmaceuticals' earnings last quarter?

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its earnings results on Monday, May, 5th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09.

When did Oric Pharmaceuticals IPO?

Oric Pharmaceuticals (ORIC) raised $75 million in an IPO on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.

Who are Oric Pharmaceuticals' major shareholders?

Oric Pharmaceuticals' top institutional shareholders include Palumbo Wealth Management LLC (0.05%). Insiders that own company stock include Jacob Chacko, Dominic Piscitelli, Pratik S Multani and Angie You.
View institutional ownership trends.

How do I buy shares of Oric Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oric Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORIC
• CIK: 1796280
• Web: www.oricpharma.com
• Phone: 650-388-5600
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oric Pharmaceuticals: $18.57
• High Price Target: $22.00
• Low Price Target: $12.00
• Potential Upside/Downside: +68.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.14%
• Return on Assets: -46.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.00
• Quick Ratio: 12.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.45 per share
• Price / Book: 3.19

Miscellaneous

• Outstanding Shares: 85,224,000
• Free Float: 79,412,000
• Market Cap: $938.32 million
• Optionable: Optionable
• Beta: 1.54